Loading ticker data...
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| 2025-11-26 | MORIKIS JOHN G | Director | Buy | 1,250 | $206.15 | $257,687.50 | +208.9% | → |
| 2025-11-26 | JOHNSON & JOHNSON | - | Sell | 6,337 | $10.03 | $63,560.11 | -0.2% | → |
| 2025-11-24 | JOHNSON & JOHNSON | - | Sell | 2,700 | $10.05 | $27,132.00 | - | → |
| 2025-11-12 | JOHNSON & JOHNSON | - | Sell | 1,000 | $10.00 | $10,000.00 | - | → |
| 2025-11-07 | JOHNSON & JOHNSON | - | Sell | 52,532 | $10.21 | $536,309.72 | -0.6% | → |
| 2025-10-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Sale+OE | 21,721 | $192.71 | $4,185,793.09 | -67.1% | → |
| 2025-09-04 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | Sale+OE | 56,471 | $177.81 | $10,040,882.63 | -24.1% | → |
| 2025-08-22 | Duato Joaquin | CEO and Chairman of the Board | Sale+OE | 125,824 | $179.21 | $22,548,654.81 | -31.3% | → |
| 2025-08-15 | Wolk Joseph J | Exec VP, CFO | Sale+OE | 16,820 | $176.91 | $2,975,570.69 | -54.6% | → |
| 2025-07-17 | REED JOHN C | EVP, Innovative Medicine, R&D | Sell | 19,137 | $163.55 | $3,129,829.56 | -64.2% | → |
| 2025-02-25 | Decker Robert J | VP Corporate Controller | Sale+OE | 6,999 | $165.88 | $1,160,994.12 | -25.0% | → |
| 2025-02-18 | Schmid Timothy | EVP, WW Chair, MedTech | Sale+OE | 403 | $156.15 | $62,928.45 | -2.6% | → |
| 2025-02-07 | Wolk Joseph J | Exec VP, CFO | Sale+OE | 13,015 | $153.89 | $2,002,878.35 | -100% | → |
| 2024-12-12 | WEINBERGER MARK A | Director | Buy | 1,000 | $147.22 | $147,220.00 | New | → |
| 2024-08-30 | Decker Robert J | VP Corporate Controller | Sale+OE | 5,635 | $165.06 | $930,113.10 | -22.9% | → |
| 2024-03-13 | Broadhurst Vanessa | EVP, Global Corp Affairs | Sell | 8,891 | $162.16 | $1,441,764.56 | -37.1% | → |
| 2024-02-16 | JOHNSON & JOHNSON | - | Sale+OE | 3,725 | $25.81 | $96,142.25 | - | → |
| 2024-02-09 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Sale+OE | 59,397 | $156.27 | $9,281,969.19 | -29.6% | → |
| 2023-07-26 | Hait William | See Remarks | Sale+OE | 14,698 | $172.00 | $2,528,056.00 | -14.3% | → |
| 2023-07-25 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 20,000 | $170.32 | $3,406,498.00 | -16.3% | → |
| 2023-06-12 | Wengel Kathryn E | EVP, Chief TO and Risk Officer | Sell | 12,465 | $160.00 | $1,994,400.00 | -15.9% | → |
| 2023-03-06 | Swanson James D. | See Remarks | Sell | 1,062 | $154.66 | $164,199.44 | -10.3% | → |
| 2022-12-13 | Wolk Joseph J | Exec VP, CFO | Sale+OE | 14,781 | $179.60 | $2,654,660.91 | -14.9% | → |
| 2022-11-30 | McEvoy Ashley | EVP, WW Chair, MedTech | Sale+OE | 73,323 | $175.47 | $12,865,800.76 | -32.0% | → |
| 2022-11-22 | Taubert Jennifer L | EVP, WW Chair, Pharmaceuticals | Sale+OE | 76,923 | $176.78 | $13,598,401.79 | -37.8% | → |
| 2022-11-18 | Decker Robert J | Controller, CAO | Sale+OE | 16,928 | $175.00 | $2,962,400.00 | -52.2% | → |
| 2022-11-09 | Wengel Kathryn E | EVP, Chief GSC Officer | Sale+OE | 16,410 | $173.42 | $2,845,772.97 | -18.7% | → |
| 2022-11-04 | Mongon Thibaut | Exec VP, WW Chair, Consumer | Sale+OE | 35,246 | $171.18 | $6,033,304.60 | -26.3% | → |
| 2022-10-24 | Fasolo Peter | Exec VP, Chief HR Officer | Sale+OE | 26 | $171.36 | $4,455.41 | - | → |
| 2022-10-24 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 963 | $170.88 | $164,561.41 | - | → |
| 2022-10-24 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 4,571 | $171.36 | $783,295.70 | -0.7% | → |
| 2022-10-24 | Fasolo Peter | Exec VP, Chief HR Officer | Sell | 1,138 | $171.17 | $194,786.76 | -0.2% | → |